Is Norditropin Approved for Noonan Syndrome?
Yes, Norditropin (somatropin), a recombinant human growth hormone from Novo Nordisk, is FDA-approved for treating growth failure in children with Noonan syndrome. The approval covers short stature associated with this genetic condition, which often involves mutations in genes like PTPN11 and leads to reduced growth hormone response.[1][2]
How Does Norditropin Work in Noonan Syndrome?
Noonan syndrome patients typically have normal growth hormone levels but impaired growth due to post-receptor signaling defects. Norditropin supplies exogenous growth hormone to boost linear growth, improving height velocity. Clinical trials showed treated children gained an average of 0.6-1.0 standard deviations in height over 2-5 years, with effects most pronounced before puberty.[3][4]
What Do Clinical Studies Show?
Key data from a randomized, double-blind trial (n=46) found Norditropin at 0.066 mg/kg/day increased height velocity from 3.9 cm/year (baseline) to 8.1 cm/year in year 1, versus 4.7 cm/year on placebo. Long-term extension studies (up to 7 years) reported final adult heights approaching population norms.[2][5] Similar results appear in European approvals via the EMA.
Who Qualifies for Treatment?
Eligibility requires:
- Confirmed Noonan syndrome diagnosis (clinical or genetic).
- Growth failure below -2 SD for age/sex.
- Open epiphyses (pre-pubertal).
- No active malignancy or untreated hypothyroidism.
Dosing starts at 0.033-0.066 mg/kg/day subcutaneously, titrated based on IGF-1 levels and growth response. Treatment continues until epiphyseal closure.[1][6]
What Side Effects Occur?
Common issues mirror general GH therapy: injection-site reactions (20-30%), headache, fluid retention, and mild glucose intolerance. Rare risks include slipped capital femoral epiphysis (monitor hip pain) and increased intracranial pressure. Noonan-specific concerns involve potential cardiac effects, given baseline risks like pulmonary stenosis—echocardiograms are recommended.[2][4]
How Does It Compare to Other GH Products?
Norditropin matches efficacy of competitors like Genotropin (Pfizer) or Humatrope (Lilly) for Noonan syndrome, all FDA-approved for this indication. Differences lie in delivery: Norditropin's FlexPro pen offers needle-free reconstitution and dose memory. Cost varies; patient assistance programs from Novo Nordisk cover copays.[1][7]
| Product | Maker | Noonan Approval | Device Feature |
|---------|--------|-----------------|---------------|
| Norditropin | Novo Nordisk | Yes | Pen with dose window |
| Genotropin | Pfizer | Yes | MiniQuick disposable |
| Omnitrope | Sandoz | Yes | Vial or syringe |
When Does Treatment End and What's the Long-Term Outlook?
Discontinue at bone age ~14-16 years or height velocity <2-3 cm/year. Adult height gains average 10-15 cm over untreated peers. Monitor IGF-1, thyroid, and glucose annually; reassess cardiac status yearly.[3][5]
Patent Status and Availability
Norditropin's key U.S. patents (e.g., formulation and device) expire between 2025-2032, per DrugPatentWatch.com. No biosimilars are approved yet for this indication.[8]
Sources
[1]: FDA Label - Norditropin
[2]: Novo Nordisk Prescribing Information
[3]: J Clin Endocrinol Metab - Noonan GH Trial (2007)
[4]: EMA Assessment Report
[5]: Long-term Study - Pediatr Endocrinol Rev (2012)
[6]: AAP Guidelines on GH Therapy
[7]: Genotropin FDA Label
[8]: DrugPatentWatch - Norditropin